Estimated rates of progression to disease.

<p>(A) The estimated rates of progression of infection with HPV-16, HPV-18 and other high-risk (OHR) HPV types to CIN1-type lesions. We compare the rates estimated from the longitudinal Swedescreen data with the model-based estimates of Jit et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049614#pone.0049614-Jit1" target="_blank">[5]</a> and Van de Velde et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049614#pone.0049614-VandeVelde1" target="_blank">[21]</a>. (B) The estimated rates of progression of CIN1-type lesions attributable to HPV-16, HPV-18 and other high-risk (OHR) HPV types to CIN2-type lesions. We compare the rates estimated from the longitudinal Swedescreen data with the model-based estimates of Jit et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049614#pone.0049614-Jit1" target="_blank">[5]</a> and Van de Velde et al. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049614#pone.0049614-VandeVelde1" target="_blank">[21]</a>.